New South Korean biocluster vies for Asian investment
This article was originally published in Scrip
South Korea has completed basic infrastructure work for a new life sciences cluster it is looking to position as a major regional centre and which will provide new competition for Singapore's Biopolis. Several national agencies, including the Korean FDA, are preparing to relocate to the site.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.